2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors

US7166623B2 · kind B2 · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• Richard Angell · London, GB
• Paul Bamborough · Stevenage, GB
• George Stuart Cockerill · Milton Keynes, GB
• Kathryn Jane Smith · Stevenage, GB
• Ann Louise Walker · Stevenage, GB

Key dates

• Filing date: Oct 16, 2002
• Grant date: Jan 23, 2007
• Expiry date: Dec 26, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I):or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.